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Current approaches to reprogram human somatic
cells to pluripotent iPSCs utilize viral transduction
of different combinations of transcription factors.
These protocols are highly inefficient because only
a small fraction of cells carry the appropriate number
and stoichiometry of proviral insertions to initiate the
reprogramming process. Here we have generated
genetically homogeneous ‘‘secondary’’ somatic
cells, which carry the reprogramming factors as
defined doxycycline (DOX)-inducible transgenes.
These cells were obtained by infecting fibroblasts
with DOX-inducible lentiviruses, isolating ‘‘primary’’
iPSCs in the presence of the drug, and finally differ-
entiating to ‘‘secondary’’ fibroblasts. When ‘‘second-
ary’’ fibroblast lines were cultured in the presence of
DOX without further viral infection, up to 2% of the
cells were reprogrammed to pluripotent ‘‘secondary’’
human iPSCs. This system will facilitate the charac-
terization of the reprogramming process and pro-
vides a unique platform for genetic or chemical
screens to enhance reprogramming or replace indi-
vidual factors.
INTRODUCTION
Reprogramming of somatic cells to a pluripotent state has been
achieved in mouse and human cells by viral transduction of the
four transcription factors Oct4, Sox2, C-myc, and Klf4 (Lowry
et al., 2008; Maherali et al., 2007; Okita et al., 2007; Park et al.,
2008; Takahashi et al., 2007; Takahashi and Yamanaka, 2006;
Wernig et al., 2007). More recently, it has been shown that
mouse and human somatic cells can also be reprogrammed in
the absence of C-myc with longer latency and substantially
decreased efficiency (Nakagawa et al., 2008; Wernig et al.,
2008b). The random integration of retroviral copies leads to
genetic heterogeneity in the infected somatic cells, with only
0.001% to 0.1% of the infected cells eventually becoming re-
programmed to a pluripotent state. These induced pluripotent
cells (iPSCs) may carry 15 or more proviral inserts (Wernig
et al., 2007), suggesting that high levels or a certain stoichiome-
try of factor expression is required to initiate reprogramming.
This need for high-titer retroviral vectors and the stochastic346 Cell Stem Cell 3, 346–353, September 11, 2008 ª2008 Elseviernature of the reprogramming process complicates mechanistic
studies as well as efforts to screen for small molecules that could
replace the virally transduced transcription factors.
In the mouse system we recently developed a DOX-inducible
‘‘secondary’’ reprogramming system to efficiently generate
iPSCs without additional viral infections. This approach helped
to gain insight into the dynamics of reprogramming and was crit-
ical for the generation of iPSCs from cell types that are known to
be difficult to culture and/or refractory to direct infection (Hanna
et al., 2008; Wernig et al., 2008a).
In order to adapt this approach to the human system, we de-
rived human iPSCs from fibroblasts infected with DOX-inducible
lentiviral vectors, which transduced either the three or four re-
programming factors. These iPSCs were differentiated in vitro
in the absence of DOX into ‘‘secondary’’ fibroblast-like cells,
which are genetically homogenous and carry the number of pro-
viral insertions that are favorable to drug-induced activation.
When cultured in the presence of DOX without subsequent virus
infection, these secondary fibroblast-like cells reprogrammed
with high efficiency into pluripotent secondary iPSCs.
RESULTS
Reprogramming of Human Fibroblasts by DOX-Inducible
Lentivirus Vectors
We and others have previously shown that DOX-inducible lenti-
viral transduction of the transcription factors Oct4, Sox2, C-myc,
and Klf4 can efficiently reprogram mouse fibroblasts to iPSCs
(Brambrink et al., 2008; Stadtfeld et al., 2008). In the following ex-
periments we used DOX-inducible lentiviral vectors carrying the
mouse (Brambrink et al., 2008) or the human cDNAs encoding
the four transcription factors OCT4, SOX2, C-MYC, and KLF4.
Human fibroblasts were transduced with either four (OCT4,
SOX2, C-MYC, KLF4, referred to as ‘‘4 factor’’ cells) or three
(OCT4, SOX2, KLF4, referred to as ‘‘3 factor’’ cells) reprogram-
ming factors. These cells were simultaneously infected with
a constitutively active lentivirus transducing the reverse tetracy-
cline transactivator (FUW-M2rtTA). The infected cells were
cultured in the presence of DOX, and iPSCs with a human ESC-
like morphology were detected after approximately 4 weeks in
4 factor and after 8 weeks in 3 factor fibroblast cultures.
Colonies were expanded into stable iPSC lines and main-
tained in the absence of DOX for more than 30 passages.
All iPSC lines showed a morphology characteristic of human
ES cells (hESCs) and uniformly expressed the pluripotency
markers Tra-1-60, SSEA4, OCT4, SOX2, and NANOGInc.
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Secondary Reprogramming of Human FibroblastsFigure 1. Characterization of DOX-Inducible iPSCs Derived from Human Fibroblasts
(A) Phase contrast picture and immunofluorescence staining of hESCs and iPSC lines A6 and D1 for pluripotency markers SSEA4, Tra-1-60, OCT4, SOX2, and
NANOG.
(B) Quantitative RT-PCR for the reactivation of the endogenous pluripotency-related genes NANOG, OCT4, and SOX2 in independent iPSC lines, hESCs, and
primary fibroblasts. Relative expression levels were normalized to the average expression of the two control hESC lines.
(C) Hematoxylin and eosin staining of teratoma sections generated from A1 iPSCs.
(D) Southern blot analysis of parental GM01660 fibroblasts, hESCs, and iPSCs for proviral integrations of XbaI-digested genomic DNA using 32P-labeld DNA
probes against OCT4, KLF4, SOX2, and C-MYC.(Figure 1A). Furthermore, quantitative RT-PCR showed that the
iPSCs had reactivated the endogenous NANOG, OCT4, and
SOX2 genes to levels comparable to those found in hESCsCell S(Figure 1B). iPSCs derived with DOX-inducible viruses showed
a normal karyotype (see Figure S1 [available online] and data
not shown).tem Cell 3, 346–353, September 11, 2008 ª2008 Elsevier Inc. 347
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independent iPSC lines were subcutaneously injected into SCID
mice and shown to form tumors after 6 to 8 weeks (Lensch et al.,
2007). Histological analysis revealed teratomas comprised of tis-
sues of all three germ layers including cartilage, skeletal muscle
(mesoderm), neural rosettes (ectoderm), and intestinal epithe-
lium (endoderm) (Figure 1C). In addition, DNA fingerprinting anal-
ysis genetically matched iPSC lines to the parental fibroblast cell
lines (data not shown). Southern blot analysis probing for proviral
integrations showed a unique pattern for each iPSC line, demon-
strating that each of these lines were derived from independently
infected fibroblasts (Figure 1D). Furthermore, this analysis
revealed that two out of the six independent 3 factor iPSC lines
(A6 and A11) carried only a few lentiviral integrations (Figure 1D).
This low number of proviral integrations is in contrast to murine
iPSC lines, which typically carry between 10 and 20 proviral inte-
grations (Wernig et al., 2007). Table S1 summarizes the charac-
teristics of iPSC lines derived from different donor cells using
different vector combinations. Using human cDNAs, we isolated
six 3 factor iPSC lines from GM01660 fibroblasts (A1, A2 A6, A9,
A11, and C1) and two 4 factor iPSC lines from MRC5 fibroblasts
(D1 and D4). To assess drug-inducible factor expression from
the integrated lentiviruses, we compared vector-specific tran-
script levels in primary infected fibroblasts and in iPSCs cultured
in the presence or absence of DOX. Two out of the three iPSC
lines tested induced transgene expression to levels comparable
to or higher than those found in primary infected fibroblasts
(Figure S2). However, one out of three lines did not show strong
transgene induction, which could suggest partial viral silencing in
some iPSCs. Transgene expression was strictly dependent on
the presence of the drug, as only few or no viral transcripts
were detected in the absence of DOX.
DOX-Inducible Secondary Fibroblasts
Previously, we generated genetically homogenous secondary
mouse fibroblasts that were efficiently converted to a pluripotent
state upon the addition of DOX but did not require infection with
viral vectors to induce the reprogramming process (Hanna et al.,
2008; Wernig et al., 2008a). In order to establish a similar system
in human cells we differentiated DOX-independent primary
iPSCs into fibroblast-like cells (see scheme in Figure 2A). Follow-
ing established protocols for differentiating human ESCs (Xu
et al., 2004), iPSCs were differentiated in the absence of DOX
and in the presence of high serum concentrations into embryoid
bodies and subsequently cultured under fibroblast growth con-
ditions. To assure elimination of undifferentiated iPSCs, which
cannot be propagated as single cells on conventional culture
dishes (Takahashi et al., 2007), fibroblast-like cells were pas-
saged at least four times using trypsin. The secondary cells
acquired a homogenous fibroblast-like morphology (Figure 2B)
and were positive for prolyl-4-hydroxylase beta expression
(P4H), an enzyme required for collagen synthesis (Figure 2B),
confirming differentiation into fibroblast-like cells. These cells
will subsequently be referred to as secondary fibroblasts. We
failed to detect cells positive for NANOG or OCT4 by immunos-
taining in any of the secondary fibroblast lines consistent with
complete differentiation of the primary iPSCs (data not shown).
In addition to these in vitro derived fibroblasts, we established348 Cell Stem Cell 3, 346–353, September 11, 2008 ª2008 Elsevierfibroblast-like cultures from human iPSC-derived teratomas
explanted into culture.
In order to confirm differentiation of the iPSCs to a somatic
epigenetic state at the molecular level, we determined the meth-
ylation levels of the OCT4 and NANOG promoters in secondary
fibroblasts. While human iPSCs showed the expected hypome-
thylation associated with active OCT4 and NANOG genes,
secondary fibroblasts showed increased promoter methylation
similar to that found in the parental fibroblast cell line (Figures
2C and S3). Together, these results indicate that the secondary
fibroblasts have the molecular and morphological characteris-
tics of somatic cells.
To assess inducible expression of the reprogramming factors,
secondary fibroblasts were treated with DOX and stained for
expression of the reprogramming factors. Most cells stained
positive for OCT4, SOX2, and KLF4 48 hr after DOX addition
(Figure 2D). However, a fraction of cells failed to activate the fac-
tors, possibly because of vector silencing. We used quantitative
RT-PCR with specific primers for the viral transgenes to quantify
vector activation. We detected robust DOX-dependent factor
expression in some secondary fibroblast lines, including A1
and C1, but less in other lines, such as A2 and D1 (Figure 2E).
Variegated vector expression within and variation of vector
induction between different secondary fibroblast lines has also
been observed in the mouse system (Wernig et al., 2008a),
suggesting that the chromosomal position of the proviruses
affects drug-inducible expression.
High Reprogramming Efficiency in Secondary
Human Fibroblasts
To assess whether addition of DOX to secondary fibroblasts was
sufficient to induce reprogramming, we plated the cells in the
presence of the drug under hESC culture conditions. After
72 hr of DOX induction, a significant fraction of cells underwent
cell death, which was more pronounced in cell lines with high
levels of transgene expression, particularly in cell line A1. After
approximately 8 days of drug induction, granulated colonies,
which did not show hESC-like morphology, appeared in the
4 factor secondary fibroblasts but were not seen in the 3 factor
fibroblasts. This closely resembled changes that we and others
observed after primary infection (Nakagawa et al., 2008; Takaha-
shi et al., 2007). After 20 to 25 days of DOX treatment, colonies
with typical hESC-like morphology emerged, which could be
expanded into secondary iPSC lines. No hESC-like colonies
appeared in any of the secondary fibroblast lines in the absence
of DOX, indicating that derivation of secondary iPSCs was
strictly dependent on DOX-induced transgene expression. Sec-
ondary iPSC lines were obtained from eight different secondary
fibroblast lines, including one teratoma-derived line (Figure 3A).
All of these lines could be maintained in the absence of DOX
and expressed the pluripotency markers Tra-1-60, SSEA4,
OCT4, SOX2, and NANOG (Figure 3B).
In order to compare reprogramming efficiencies of the differ-
ent cell lines, we plated the 3 factor secondary fibroblast cell
lines A1, A2, and C1 and the 4 factor line D1 at three different
densities onto feeder cells. Reprogramming efficiencies were
determined after 20 or 28 days of DOX treatment by counting
SSEA4/Tra-1-60 double-positive colonies (Figure 3C). To ascer-
tain whether Tra-1-60 and SSEA4 double-positive cells wereInc.
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Secondary Reprogramming of Human FibroblastsFigure 2. Characterization of Genetically Identical Secondary Fibroblasts Derived from iPSCs
(A) Timeline depicting the generation and reprogramming of secondary iPSC-derived fibroblasts.
(B) Phase contrast picture and immunostaining of C1 secondary fibroblasts, primary fibroblasts, and epithelial cells (EpRas) for the fibroblast marker prolyl-4-
hydroxylase beta (P4H) (in green).
(C) Methylation analysis of the OCT4 promoter region. Light gray squares indicate unmethylated CpGs and black squares indicate methylated CpGs in the OCT4
promoter of iPSCs, hESCs, and primary and secondary fibroblasts.
(D) Immunostaining for DOX-induced transgene expression of OCT4, KLF4, and SOX2 in C1 secondary fibroblasts 48 hr after drug administration.
(E) Quantitative RT-PCR for DOX-dependent transgene expression of OCT4, KLF4, SOX2, and C-MYC in secondary fibroblasts and primary infected fibroblasts.
Relative expression levels were normalized to DOX-induced expression in primary infected fibroblasts.valid markers for iPSCs, we performed additional coimmunos-
taining for Tra-1-60 and NANOG on a subset of the cells (Fig-
ure 3D). More than 80% of the Tra-1-60-positive colonies also
stained positive for NANOG, demonstrating that Tra-1-60/
SSEA4 double positive staining can be used as a valid marker
for reprogrammed iPSCs. Using this criterion we found that inde-Cellpendent secondary fibroblast lines had reprogramming efficien-
cies between 0.26% and 2.0%, which is in the same range as
reprogramming efficiencies of secondary mouse fibroblasts
(Wernig et al., 2008a). Reprogramming efficiencies of different
secondary cell lines appeared to be positively correlated with
high transgene expression after DOX induction. However, A1Stem Cell 3, 346–353, September 11, 2008 ª2008 Elsevier Inc. 349
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Secondary Reprogramming of Human FibroblastsFigure 3. DOX-Induced Reprogramming of Secondary Fibroblast Lines
(A) Summary of reprogramming efficiency of in vitro differentiated and teratoma-derived secondary fibroblasts. Reprogramming efficiencies are categorized into
‘‘low,’’ indicating efficiency of <0.1%, ‘‘medium’’ (0.1%–0.5%), and ‘‘high’’ (>0.5%).
(B) Phase contrast picture and immunofluorescence staining of secondary iPSC line A6 for pluripotency markers SSEA4, Tra-1-60, OCT4, SOX2, and NANOG.
(C) Reprogramming efficiency of secondary fibroblasts A1, A2, C1, and D1 at 28 days (A1, A2) or 20 days (C1, D1) after DOX induction as determined by immu-
nostaining for Tra-1-60 and SSEA4. Efficiencies were calculated as the fraction of Tra-1-60/SSEA4-positive colonies to cells seeded. Error bars indicate the SEM
generated from triplicates of the same experiment.
(D) Immunostaining of C1 secondary iPSC colonies for Tra-1-60/SSEA4 and Tra-1-60/NANOG 20 days after DOX induction.secondary fibroblasts, which displayed high transgene expres-
sion, particularly for SOX2 (Figure 2E), showed only a moderate
reprogramming efficiency. This may have been due to the in-
creased cell death observed in this cell line after addition of DOX.
Transgene Expression Is Required for at Least 8 Days
to Induce Reprogramming
To quantitatively determine the kinetics of reprogramming, we
stained secondary fibroblasts at different times after addition
of DOX for the expression of different pluripotency markers
(experimental overview in Figure 4A). The first cells staining pos-
itive for Tra-1-60 appeared after 6 days in C1 and 8 days in A2
secondary fibroblasts (Figures 4B and 4C), whereas NANOG-
positive cells were first detected at 11 days after drug exposure
(Figure 4C). The number of Tra-1-60-positive colonies increased
with prolonged exposure to DOX (Figure 4G).
To determine how long after DOX induction cells acquire
a self-sustaining state that is independent of transgene expres-
sion, we cultured two independent secondary fibroblast lines
(A2 and C1) in the presence of DOX and withdrew the drug at dif-
ferent times after induction (Figure 4D). Reprogramming was
assessed 20 days after initial DOX addition. Colonies with
hESC-like morphology appeared in C1 secondary fibroblasts
exposed to DOX for 8 days, while A2 secondary fibroblasts
required at least 14 days of DOX. These time points are only
a few days after the appearance of Tra-1-60- and NANOG-pos-
itive cells in each of these lines. No colonies were detected on
plates that were not exposed to DOX or were treated for less
than 8 days. Individual colonies from line C1 treated with DOX
for 8 days and from line A2 treated with DOX for 14 days were350 Cell Stem Cell 3, 346–353, September 11, 2008 ª2008 Elsevier Ipicked and expanded (n = 10) and shown to give rise to second-
ary iPSC lines. Secondary iPSC lines expressed the pluripotency
specific markers SSEA4, Tra-1-60, OCT4, SOX2, and NANOG
(Figure 4E and S4). The number of reprogrammed cells in-
creased with prolonged exposure to DOX as shown by alkaline
phosphatase (AP) staining (Figure 4F) and quantification of Tra-
1-60-positive colonies (Figure 4H). Interestingly, the number of
reprogrammed colonies found after 20 days was similar to the
number of Tra-1-60-positive colonies detected on the day
when DOX was withdrawn (compare Figures 4G and 4H). This
correlation suggests that as early as 8 days after DOX addition
Tra-1-60-positive cells are primed to become pluripotent.
In summary, our results demonstrate that secondary fibro-
blasts can generate iPSCs when cultured in the presence of
DOX with up to 2% efficiency. This is more than two orders of
magnitude higher than that achieved by conventional viral trans-
duction.
DISCUSSION
Current protocols for reprogramming human somatic cells are
based on viral vector-mediated transduction of the reprogram-
ming factors and are highly inefficient. This is especially true
for 3 factor reprogramming events, without the oncogene
C-MYC, which were previously reported to occur with a fre-
quency of <0.001% (Nakagawa et al., 2008). In this paper
we developed a secondary reprogramming system in human
somatic cells, based on an analogous approach in the
mouse system, to overcome some of the limitations of current
reprogramming protocols. Human fibroblasts infected withnc.
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Secondary Reprogramming of Human FibroblastsDOX-inducible vectors transducing either the three or four re-
programming factors gave rise to iPSCs with approximately
the same low efficiency as reported previously. These primary
iPSCs were differentiated in the absence of DOX into second-
ary fibroblasts. When cultured in the presence of DOX, these
genetically distinct secondary fibroblast lines, carrying different
combinations of proviruses, gave rise to secondary iPSCs with
efficiencies ranging from 0.26% to 2%, an improvement over
the reported efficiencies found by primary infections by more
than two orders of magnitude. The fact that we observed
a slightly faster time course of reprogramming in the second-
ary compared to the primary system is likely the result of the
very low efficiency and stochastic nature of primary reprog-
ramming with three factors. The time course of reprogramming
that we observed in the secondary system is in agreement
with previous reports of primary reprogramming (Nakagawa
et al., 2008; Park et al., 2008; Takahashi et al., 2007; Yu
et al., 2007).
Reprogrammed secondary iPSCs expressed pluripotency
markers such as AP, Tra-1-60, OCT4, and NANOG. The finding
that, in secondary fibroblasts, OCT4 and NANOG promoters
are hypermethylated to a similar extent as primary fibroblasts
suggests that the reactivation of OCT4 and NANOG during sec-
ondary reprogramming depends on the reestablishment of the
autoregulatory loop involving activation of the four endogenous
pluripotency factors OCT4, NANOG, SOX2, and TCF3 (Jaenisch
and Young, 2008). This argues that the same molecular process
drives primary and secondary reprogramming.
In contrast to mouse cells, nuclear transfer-mediated reprog-
ramming of human cells has not yet been achieved. Similarly,
conventional reprogramming of human cells is vastly less effi-
cient than that of mouse cells. The reasons for these differences
are not clear and could be due to inherent differences between
human andmouse cells and/or to technical issues such as differ-
ential susceptibility of the cells to culture conditions. However,
the reprogramming efficiency of human secondary fibroblasts
Figure 4. Kinetics and Requirement for
Transgene Expression of Secondary Fibro-
blast Reprogramming
(A) Experimental outline of reprogramming kinetics
experiment. Secondary fibroblasts were plated in
DOX-free fibroblast medium on day 2 (black
bars). After 2 days (day 0), medium was changed
to hESC medium containing DOX (green bars).
Cells were fixed at the indicated time points and
stained for pluripotency markers.
(B) Immunostaining of C1 secondary fibroblasts
for Tra-1-60 at indicated days after DOX induction.
Inset shows magnification of the same picture.
(C) Immunostaining of A2 secondary fibroblasts
for Tra-1-60 and NANOG at the indicated days
after DOX induction (upper panel). Lower panel
shows a magnification of NANOG and DAPI stain-
ing of the same area.
(D) Experimental outline of the DOXwithdrawal ex-
periment. Secondary fibroblasts were plated in fi-
broblast medium without DOX on day 2 (black
bars). After 2 days (day 0), medium was changed
to human ESC medium containing DOX (green
bars). Medium was changed to hESC medium
without DOX at the indicated time points (red
bars). Secondary iPSC colonies were picked on
day 20 for all DOX conditions.
(E) Immunostaining of secondary C1 iPSCs for
SSEA4, Tra-1-60, OCT4, and NANOG, which
were derived by DOX induction for 8 days.
(F) Alkaline phosphatase staining of C1 secondary
fibroblasts at day 20 after exposure to DOX. The
day indicates the time when DOX was withdrawn
from the culture medium.
(G) Number of reprogrammed colonies at different
times after addition of DOX. The number of colo-
nies on the indicated day was determined by
immunostaining for Tra-1-60. Error bars indicate
the SEM generated from triplicates of the same
experiment.
(H) Number of reprogrammed colonies at day 20
after DOX addition. DOX was withdrawn from the
culture medium at the indicated time points. The
number of colonies was determined by immunos-
taining for Tra-1-60. Error bars indicate the SEM
generated from triplicates of the same experiment.Cell Stem Cell 3, 346–353, September 11, 2008 ª2008 Elsevier Inc. 351
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arguing against inherent differences of mouse and human cells
to epigenetic reprogramming.
The first reprogrammed cells from secondary fibroblasts,
although very infrequent, appeared already at 8 to 11 days after
DOX exposure, as indicated by AP and Tra-1-60 expression.
However, we noted that, during reprogramming of human sec-
ondary fibroblasts, AP and Tra-1-60 were activated only slightly
earlier than NANOG, which is different from the sequential ap-
pearance of these markers in mouse cells (Brambrink et al.,
2008; Stadtfeld et al., 2008; Wernig et al., 2008a). The human
secondary system, with its greatly increased efficiency, will allow
detailed study of the role and importance of NANOG and other
pluripotency markers during the reprogramming process of
human cells. Nevertheless, it seems prudent to also investigate
the kinetics of NANOG activation in human cells after primary
infection.
The drug-inducible system described here represents a novel,
predictable, and highly reproducible platform to study the kinet-
ics of iPSC generation. This should facilitate the study of early
molecular events leading to epigenetic reprogramming of human
somatic cells. In addition, the genetic homogeneity of secondary
cells makes chemical and genetic screening approaches to
enhance reprogramming efficiency feasible. Since the reprog-
rammed state is not dependent on continued expression of the
exogenous factors, the transgenes can be genetically engi-
neered and excised, allowing the generation of secondary cells
that lack a particular reprogramming factor (Hanna et al.,
2007). This will enable screens for compounds that can replace
the original reprogramming factors.
EXPERIMENTAL PROCEDURES
For more details, see the Supplemental Experimental Procedures.
Lentiviral Infection and iPSC Derivation
VSVG-coated lentiviruses were generated in 293 cells as described previously
(Brambrink et al., 2008). Briefly, culture medium was changed 12 hr posttrans-
fection, and virus-containing supernatant was collected 60–72 hr posttrans-
fection. Viral supernatant was filtered through a 0.45 mmfilter. Virus-containing
supernatants were pooled for 3 and 4 factor infections and supplemented with
FUW-M2rtTA virus and an equal volume of fresh culture medium. Human fibro-
blasts (13 106) were seeded 24 hr before transduction in T75 flasks. Four con-
secutive infections were performed over a period of 48 hr in the presence of
2 mg/ml of polybrene. Culture medium was changed 12 hr after the last infec-
tion. Five days after transduction, fibroblasts were passaged using trypsin and
replated at different densities between 53 104 and 53 105 cells per 10 cm on
gelatin-coated dishes or MEF feeder layers. To induce reprogramming, culture
medium was replaced 48 hr later by human ESC medium supplemented with
doxycycline (Sigma-Aldrich; 2 mg/ml). Human iPSCs colonies were picked
manually based on morphology between 4 and 8 weeks after doxycycline
induction and manually maintained and passaged according to human ESC
protocols in the absence of doxycycline.
Derivation of Secondary Fibroblast-like Cells
Human iPSCs were differentiated into fibroblast-like cells as described previ-
ously (Xu et al., 2004). iPSCswere differentiated by embryoid body formation in
fibroblast medium for 5 days and subsequently plated onto adherent tissue
culture dishes and passaged according to primary fibroblast protocols using
trypsin for at least four passages before the start of experiments. For the der-
ivation of secondary iPSCs, secondary fibroblasts were plated at densities be-
tween 13 103 and 13 104 per 35 mm on gelatin-coated dishes or MEF feeder
layers. Forty-eight hours later, fibroblast mediumwas replaced by human ESC352 Cell Stem Cell 3, 346–353, September 11, 2008 ª2008 Elsevier Imedium supplemented with doxycycline (Sigma-Aldrich; 2 mg/ml). For the ki-
netics experiments (Figures 4A–4C and 4G), cells were fixed at the indicated
time points and immunostained after the completion of the experiment (see
Supplemental Experimental Procedures for immunostaining procedures).
For DOX withdrawal experiments (Figures 4D–4F and 4H), medium was
replaced with human ES medium without DOX at the indicated times.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, one
table, and four figures and can be found with this article online at http://
www.cellstemcell.com/cgi/content/full/3/3/346/DC1/.
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